Tempus xT CDx is a sophisticated cancer profiling tool designed to enhance precision oncology. This assay uses next-generation sequencing to analyze over 648 genes and is specifically crafted to provide actionable genomic data for patients with solid tumors. The xT CDx panel examines tumor samples alongside matched normal samples, such as blood or saliva, to deliver comprehensive mutation profiling. This FDA-approved diagnostic tool also identifies microsatellite instability (MSI) status, offering valuable insights into potential therapeutic paths for cancer treatment.<br/><br/>Tempus xT CDx maximizes the detection of clinically relevant mutations, thereby aligning patients with the most effective targeted therapies. Its robust design aids clinicians in identifying both somatic and germline mutations, enabling a more precise approach to cancer management. Moreover, the integration of MSI status helps in recognizing the responsiveness of tumors to certain immunotherapies, promoting personalized treatment strategies.<br/><br/>The test supports the clinical decision-making process by differentiating actionable variants that practitioners can consider for treatment adjustments. Tailored to meet rigorous clinical guidelines, this assay is a vital component in the treatment continuum, guiding both initial therapy choices and adjustments in ongoing patient management efforts.
